CA3216629A1 - Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents - Google Patents

Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents Download PDF

Info

Publication number
CA3216629A1
CA3216629A1 CA3216629A CA3216629A CA3216629A1 CA 3216629 A1 CA3216629 A1 CA 3216629A1 CA 3216629 A CA3216629 A CA 3216629A CA 3216629 A CA3216629 A CA 3216629A CA 3216629 A1 CA3216629 A1 CA 3216629A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
mmol
haloalkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216629A
Other languages
English (en)
French (fr)
Inventor
Ki Seon Baek
Ja Heouk Khoo
Soongyu Choi
Young Whan Park
Simon Ward
Darren Le Grand
Ryan West
Penelope TURNER
Samuele MARAMAI
Tristan REUILLON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avelos Therapeutics Inc
Original Assignee
Avelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelos Therapeutics Inc filed Critical Avelos Therapeutics Inc
Publication of CA3216629A1 publication Critical patent/CA3216629A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3216629A 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents Pending CA3216629A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
GB2108249.0 2021-06-09
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
CA3216629A1 true CA3216629A1 (en) 2022-12-15

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216629A Pending CA3216629A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Country Status (10)

Country Link
US (1) US20240300936A1 (https=)
EP (1) EP4352049A4 (https=)
JP (1) JP2024522201A (https=)
KR (1) KR20240006692A (https=)
CN (1) CN117529476A (https=)
AU (1) AU2022291332A1 (https=)
CA (1) CA3216629A1 (https=)
GB (1) GB202108249D0 (https=)
MX (1) MX2023014784A (https=)
WO (1) WO2022260441A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250096877A (ko) * 2022-12-12 2025-06-27 아벨로스테라퓨틱스 주식회사 치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도
WO2024137979A2 (en) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
JP5856151B2 (ja) * 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
US9604937B2 (en) * 2012-11-27 2017-03-28 Thomas Helledays Stiftelse For Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂

Also Published As

Publication number Publication date
EP4352049A4 (en) 2025-05-21
EP4352049A1 (en) 2024-04-17
CN117529476A (zh) 2024-02-06
WO2022260441A1 (en) 2022-12-15
KR20240006692A (ko) 2024-01-15
JP2024522201A (ja) 2024-06-11
GB202108249D0 (en) 2021-07-21
US20240300936A1 (en) 2024-09-12
AU2022291332A1 (en) 2023-12-21
MX2023014784A (es) 2024-03-25

Similar Documents

Publication Publication Date Title
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
AU2017311645B2 (en) Pyridopyrimdinone CDK2/4/6 inhibitors
JP6530792B2 (ja) Ｓｙｋ阻害剤
AU2024219343A1 (en) Antimicrobial organosilanes
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI880472B (zh) Tlr7/8拮抗劑及其用途
IL274938B1 (en) New compounds and their pharmaceutical preparations for the treatment of diseases
EA035823B1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
CA3180079A1 (en) Il-17a modulators
TW202122382A (zh) 乙內醯脲衍生物
CA3185634A1 (en) Tricyclic heterocycles
KR20150090044A (ko) 아자퀴나졸린 카복사미드 유도체
US20200148667A1 (en) Substituted heterocyclic derivatives as pi3k inhibitors
JP7812861B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン
CA3216629A1 (en) Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
AU2023279857A1 (en) Novel par-2 inhibitors
CA3150516A1 (en) DNA-PK INHIBITOR COMPOUNDS
CA3236433A1 (en) Tricyclic heterocycles
EP4305040A1 (en) Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors
US20250352549A1 (en) Substituted heterocyclic compound derivatives and their pharmaceutical use
EA036060B1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6
WO2022128850A1 (en) Novel isoquinoline derivatives and pharmaceutical copositions thereof for the treatment of diseases
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
NZ787918A (en) Pyridopyrimdinone CDK2/4/6 inhibitors
HK1242303A1 (en) Heteroaryl compounds as irak inhibitors and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414